2m 2m 2m 2m 2m 2m 2m
Collegium Pharma (COLL)
NASDAQ
$31.06+$0.58 (+1.90%)
Price as of Jun 03, 2026 4:10 PM EDT- $1.1BMarket Cap
- 4.28%1-Year Change
- Drug Manufacturers - Specialty & GenericIndustry
Collegium Pharma (COLL)
$31.06+$0.58 (+1.90%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 780.6M +23.62% | 631.4M +11.41% | 566.8M +22.17% | 463.9M +67.56% | |
Cost of Revenue | 317.3M +24.87% | 254.1M +5.61% | 240.6M -5.44% | 254.4M +101.54% | |
Gross Profit | 463.3M +22.77% | 377.3M +15.69% | 326.2M +55.70% | 209.5M +39.09% | |
Sales and Marketing Expense | 284.8M +35.39% | 210.4M +32.13% | 159.2M -7.54% | 172.2M +44.74% | |
Research and Development Expense | N/A N/A | 0 N/A | 0 +100.00% | -4.0M -57.86% | |
Depreciation and Amortization Expense | 221.9M +5,654.46% | 3.9M +10.30% | 3.5M +30.25% | 2.7M -96.00% | |
Total Operating Expenses | 283.6M +36.72% | 207.4M +30.30% | 159.2M -9.63% | 176.2M +32.47% | |
Operating Profit | 179.6M +5.73% | 169.9M +1.76% | 167.0M +401.10% | 33.3M +89.01% | |
Interest Income | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Expense | -58.4M -2.41% | -59.8M -28.22% | -83.3M +31.84% | -63.2M +200.81% | |
Interest Income and Expense and Net | -58.4M -2.41% | -59.8M -28.22% | -83.3M +31.84% | -63.2M +200.81% | |
Total Nonoperating Income and Expense | N/A N/A | N/A N/A | 83.3M +31.84% | 63.2M +200.81% | |
Income before Taxes | 92.6M -6.04% | 98.6M +30.15% | 75.7M +362.53% | -28.8M +754.98% | |
Income Taxes | 29.7M +1.26% | 29.4M +6.53% | 27.6M +817.24% | -3.8M -94.87% | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | 62.9M -9.13% | 69.2M +43.68% | 48.2M +292.60% | -25.0M -134.96% | |
Net Income from Continuing Operations Applicable to Common | 92.6M -6.04% | 98.6M +30.15% | 75.7M +362.53% | -28.8M +754.98% | |
Basic EPS and Net Income | 1.98 -7.48% | 2.14 +49.65% | 1.43 +293.24% | -0.74 -136.10% | |
Diluted EPS and Net Income | 1.73 -6.99% | 1.86 +44.19% | 1.29 +274.32% | -0.74 -139.78% | |
Basic Weighted Average Shares | 31.7M -1.76% | 32.3M -4.35% | 33.7M -0.26% | 33.8M -3.17% | |
Diluted Weighted Average Shares | 39.7M -1.79% | 40.4M -3.26% | 41.8M +23.53% | 33.8M -17.58% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 231.3M +227.71% | 70.6M -70.47% | 238.9M +37.57% | 173.7M -6.83% | |
Short-Term Investments | 155.4M +68.58% | 92.2M +28.77% | 71.6M N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 386.7M +137.57% | 162.8M -47.59% | 310.5M +78.80% | 173.7M -6.83% | |
Total Current Assets | 691.4M +43.37% | 482.3M -10.29% | 537.6M +28.00% | 420.0M +33.10% | |
Accumulated Depreciation | 16.5M +22.23% | 13.5M +39.84% | 9.7M +53.06% | 6.3M +34.65% | |
Property and Plant and Equipment and Net | 12.0M -16.16% | 14.3M -10.35% | 16.0M -18.12% | 19.5M +0.15% | |
Total Long-Term Assets | 20.2M +141.31% | 8.4M +914.30% | 825,000 +725.00% | 100,000 +14.94% | |
Total Assets | 1.7B -0.41% | 1.7B +45.51% | 1.1B -2.63% | 1.2B +69.65% | |
Income Taxes Payable | 32.4M -48.28% | 62.7M -14.44% | 73.3M -22.97% | 95.2M +15,199.36% | |
Total Short-Term Debt | 29.0M -55.10% | 64.6M -64.77% | 183.3M +12.82% | 162.5M +236.07% | |
Total Current Liabilities | 440.0M -13.64% | 509.5M +11.27% | 457.9M +5.58% | 433.7M +55.14% | |
Total Long-Term Debt | 780.3M -0.96% | 787.9M +62.84% | 483.8M -10.14% | 538.5M +167.05% | |
Total Long-Term Liabilities | 13.2M -14.78% | 15.5M +153.74% | 6.1M -13.89% | 7.1M -10.55% | |
Total Liabilities | 1.4B -5.55% | 1.4B +51.36% | 947.9M -3.21% | 979.3M +100.20% | |
Retained Earnings | -101.1M -38.34% | -164.0M -29.67% | -233.2M -17.12% | -281.3M +9.75% | |
Total Stockholders Equity | 301.7M +31.83% | 228.8M +17.10% | 195.4M +0.30% | 194.8M -3.98% | |
Total Shares Outstanding | 31.7M +0.85% | 31.4M -1.34% | 31.9M -5.85% | 33.8M +0.58% | |
Cash Flow | |||||
Cash from Operating Activities | 329.3M +60.66% | 205.0M -25.39% | 274.7M +121.16% | 124.2M +19.96% | |
Capital Expenditures | 1.7M +5.33% | 1.7M +258.35% | 461,000 -71.58% | 1.6M -16.56% | |
Cash from Investing Activities | -63.5M -77.92% | -287.8M +306.37% | -70.8M -87.66% | -573.7M +29,410.85% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | -110.2M +81.91% | -60.6M -56.77% | -140.2M -132.10% | 436.7M +589.04% | |
Financials Ratio | |||||
Gross Margin | 59.35% -0.69% | 59.76% +3.84% | 57.55% +27.45% | 45.15% -17.00% | |
Operating Margin | 23.01% -14.47% | 26.91% -8.67% | 29.46% +310.18% | 7.18% +12.80% | |
Return on Assets | 3.79% -23.19% | 4.93% +18.63% | 4.16% +255.11% | -2.68% -125.03% | |
Return on Equity | 23.70% -27.33% | 32.62% +32.17% | 24.68% +296.30% | -12.57% -134.19% | |
Revenue Growth | 23.62% +106.93% | 11.41% -48.51% | 22.17% -67.19% | 67.56% +731.89% | |
Current Ratio | 1.57 +66.01% | 0.95 -19.38% | 1.17 +21.24% | 0.97 -14.21% | |
Cash Ratio | 0.53 +279.42% | 0.14 -73.46% | 0.52 +30.29% | 0.40 -39.94% | |
Debt-to-Equity Ratio | 2.68 -27.98% | 3.73 +9.12% | 3.41 -5.11% | 3.60 +192.03% | |
Debt-to-Assets Ratio | 0.49 -4.66% | 0.51 -12.19% | 0.58 -2.26% | 0.60 +65.28% | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow